BSD Medical's systems used to treat pancreatic cancer in Phase III study
A Phase III clinical study is now underway that involves the combined use of hyperthermia therapy and chemotherapy in treating patients with pancreatic cancer with aid from BSD Medical, a developer of systems used to provide cancer therapies requiring precision-focused heat through radio-frequency/microwave technologies.

The study, which was presented during the American Society of Clinical Oncology (ASCO) conference in Chicago this week, follows the successful conclusion of a Phase II clinical trial conducted in Munich, Germany, using a combination of hyperthermia therapy and chemotherapy to treat patients with pancreatic cancer, according to BSD.

All hyperthermia treatments used for the study will be delivered using BSD-2000 hyperthermia systems, according to a team of researchers led by Rolf D. Issels, MD, PhD, of The Ludwig Maximilian University Munich -Klinikum Großhadern.

While the use of hyperthermia therapy in treating some other forms of cancer has been heavily researched, little has been known about the potential of the therapy in treating pancreatic cancer patients, a deadly cancer for which better treatments are urgently needed, the Salt Lake City-based company said.

ASCO is the world's leading professional organization representing physicians who treat cancer. More than 25,000 oncology practitioners belong to ASCO, from all oncology disciplines.

The European Society for Hyperthermic Oncology (ESHO) and the Helmholtz Center Munich support the study.